Insulet Co. (NASDAQ:PODD) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. reduced its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 35.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,734 shares of the medical instruments supplier's stock after selling 23,265 shares during the quarter. Victory Capital Management Inc. owned about 0.06% of Insulet worth $9,272,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Parkside Financial Bank & Trust increased its position in Insulet by 251.0% during the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 123 shares in the last quarter. Allworth Financial LP increased its holdings in shares of Insulet by 104.5% in the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 92 shares during the last quarter. Wolff Wiese Magana LLC raised its position in shares of Insulet by 2,680.0% during the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier's stock valued at $30,000 after acquiring an additional 134 shares in the last quarter. Lindbrook Capital LLC boosted its holdings in Insulet by 64.1% in the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier's stock worth $42,000 after purchasing an additional 75 shares during the period. Finally, Turtle Creek Wealth Advisors LLC acquired a new position in Insulet during the 4th quarter valued at about $43,000.

Insulet Stock Performance

PODD traded up $11.25 during midday trading on Tuesday, reaching $172.27. The company had a trading volume of 2,319,742 shares, compared to its average volume of 911,688. The business has a 50-day moving average price of $170.39 and a two-hundred day moving average price of $182.53. The stock has a market cap of $12.06 billion, a PE ratio of 51.75, a P/E/G ratio of 2.91 and a beta of 1.00. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $331.65. The company has a debt-to-equity ratio of 1.72, a quick ratio of 2.75 and a current ratio of 3.74.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.34. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The firm had revenue of $441.70 million for the quarter, compared to analysts' expectations of $424.05 million. During the same quarter in the prior year, the firm posted $0.23 earnings per share. The business's quarterly revenue was up 23.3% on a year-over-year basis. On average, sell-side analysts expect that Insulet Co. will post 3.16 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of the firm's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the transaction, the director now directly owns 2,567 shares in the company, valued at approximately $418,215.64. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.47% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PODD. Jefferies Financial Group lifted their price target on Insulet from $255.00 to $260.00 and gave the company a "buy" rating in a report on Friday. Barclays decreased their price target on Insulet from $213.00 to $200.00 and set an "equal weight" rating for the company in a research note on Monday. JPMorgan Chase & Co. lifted their price objective on shares of Insulet from $190.00 to $225.00 and gave the company an "overweight" rating in a research note on Friday, February 23rd. Canaccord Genuity Group boosted their price target on shares of Insulet from $226.00 to $234.00 and gave the stock a "buy" rating in a research report on Friday. Finally, Piper Sandler lowered their price target on Insulet from $250.00 to $230.00 and set an "overweight" rating on the stock in a research report on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $239.44.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.